Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Mackenzie Financial Corp

Mackenzie Financial Corp increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 68.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 61,261 shares of the biotechnology company’s stock after purchasing an additional 24,836 shares during the quarter. Mackenzie Financial Corp owned 0.06% of Sarepta Therapeutics worth $9,679,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the company. Capital International Investors raised its stake in shares of Sarepta Therapeutics by 160.0% during the 4th quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock worth $457,221,000 after buying an additional 2,917,797 shares during the last quarter. Farallon Capital Management LLC increased its holdings in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after acquiring an additional 1,243,427 shares in the last quarter. Avoro Capital Advisors LLC raised its position in Sarepta Therapeutics by 7.9% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after acquiring an additional 319,444 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Sarepta Therapeutics by 693.7% in the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock valued at $57,356,000 after purchasing an additional 317,277 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Sarepta Therapeutics by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock valued at $850,139,000 after buying an additional 243,180 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Michael Andrew Chambers purchased 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock in a transaction on Friday, August 16th. The shares were purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the acquisition, the director now owns 284,034 shares in the company, valued at $38,003,749.20. The disclosure for this purchase can be found here. Corporate insiders own 7.70% of the company’s stock.

Analysts Set New Price Targets

SRPT has been the topic of a number of recent research reports. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Sarepta Therapeutics in a report on Thursday, September 19th. BMO Capital Markets upped their target price on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. UBS Group raised their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Bank of America boosted their target price on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the company a “buy” rating in a report on Friday, June 21st. Finally, Robert W. Baird upped their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, June 21st. Three research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $187.39.

Sarepta Therapeutics Stock Up 0.3 %

Shares of NASDAQ:SRPT opened at $124.89 on Tuesday. The company has a market capitalization of $11.81 billion, a price-to-earnings ratio of 1,135.36 and a beta of 0.81. The company has a 50 day moving average of $134.56 and a two-hundred day moving average of $132.86. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same period last year, the business earned ($0.27) EPS. The business’s revenue was up 38.9% on a year-over-year basis. As a group, analysts forecast that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.